| Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. | |
| | |
MedLine Citation:
|
PMID: 19644383 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: The HIV-1 epidemic in African countries is largely due to non-B HIV-1 subtypes. Patterns and frequency of antiretroviral drug resistance mutations observed in these countries may differ from those in the developed world, where HIV-1 subtype B predominates. METHODS: HIV-1 subtype and drug resistance mutations were assayed among Nigerian patients with treatment failure on first-line therapy (plasma HIV RNA >1000 copies/mL). Sequence analysis of the reverse transcriptase and protease gene revealed drug resistance mutations and HIV-1 viral subtype. Specific patterns of mutations and clinical characteristics are described in patients with the K65R mutation. RESULTS: Since 2005, 338 patients were evaluated. The most prevalent subtypes were CRF02_AG [152 of 338 (44.9%)] and G [128 of 338 (37.9%)]. Three hundred seven of 338 (90.8%) patients had previously received stavudine and/or zidovudine + lamivudine + efavirenz or nevirapine; 41 of 338 (12.1%) had received tenofovir (TDF). The most common nucleoside reverse transcriptase inhibitor mutations observed were M184V (301, 89.1%) and K70R (91, 26.9%). The K65R mutation was present in 37 of 338 patients (10.9%). The Q151M (P < 0.05), K219R, and T69del (P < 0.01) mutations were more common in patients with K65R who had not received TDF. CONCLUSIONS: The K65R mutation is increasingly recognized and is a challenging finding among patients with non-B HIV subtypes, whether or not they have been exposed to TDF. |
| | |
Authors:
|
Claudia A Hawkins; Beth Chaplin; John Idoko; Ernest Ekong; Isaac Adewole; Wadzani Gashau; Robert L Murphy; Phyllis Kanki; |
Related Documents
:
|
7568233 - Functional haplodiploidy: a mechanism for the spread of insecticide resistance in an im... 16415113 - Mutational analysis of polar amino acid residues within predicted transmembrane helices... 8297933 - Frar course on laboratory approaches to aging. genetic influences on aging in mammals a... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of acquired immune deficiency syndromes (1999) Volume: 52 ISSN: 1944-7884 ISO Abbreviation: J. Acquir. Immune Defic. Syndr. Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2010-02-01 Completed Date: 2010-02-16 Revised Date: 2011-05-16 |
Medline Journal Info:
|
Nlm Unique ID: 100892005 Medline TA: J Acquir Immune Defic Syndr Country: United States |
Other Details:
|
Languages: eng Pagination: 228-34 Citation Subset: IM; X |
Affiliation:
|
Northwestern University, Chicago, IL 60611, USA. c-hawkins@md.northwestern.edu |
| Data Bank Information | |
Bank Name/Acc. No.:
|
GENBANK/FJ931123; FJ931124; FJ931125; FJ931126; FJ931127; FJ931128; FJ931129; FJ931130; FJ931131; FJ931132; FJ931133; FJ931134; FJ931135; FJ931136; FJ931137; FJ931138; FJ931139; FJ931140; FJ931141; FJ931142; FJ931143; FJ931144; FJ931145; FJ931146; FJ931147; FJ931148; FJ931149; FJ931150; FJ931151; FJ931152; FJ931153; FJ931154; FJ931155; FJ931156; FJ931157; FJ931158; FJ931159; FJ931160; FJ931161; FJ931162; FJ931163; FJ931164; FJ931165; FJ931166; FJ931167; FJ931168; FJ931169; FJ931170; FJ931171; FJ931172; FJ931173; FJ931174; FJ931175; FJ931176; FJ931177; FJ931178; FJ931179; FJ931180; FJ931181; FJ931182; FJ931183; FJ931184; FJ931185; FJ931186; FJ931187; FJ931188; FJ931189; FJ931190; FJ931191; FJ931192; FJ931193; FJ931194; FJ931195; FJ931196; FJ931197; FJ931198; FJ931199; FJ931200; FJ931201; FJ931202; FJ931203; FJ931204; FJ931205; FJ931206; FJ931207; FJ931208; FJ931209; FJ931210; FJ931211; FJ931212; FJ931213; FJ931214; FJ931215; FJ931216; FJ931217; FJ931218; FJ931219; FJ931220; FJ931221; FJ931222; FJ931223; FJ931224; FJ931225; FJ931226; FJ931227; FJ931228; FJ931229; FJ931230; FJ931231; FJ931232; FJ931233; FJ931234; FJ931235; FJ931236; FJ931237; FJ931238; FJ931239; FJ931240; FJ931241; FJ931242; FJ931243; FJ931244; FJ931245; FJ931246; FJ931247; FJ931248; FJ931249; FJ931250; FJ931251; FJ931252; FJ931253; FJ931254; FJ931255; FJ931256; FJ931257; FJ931258; FJ931259; FJ931260; FJ931261; FJ931262; FJ931263; FJ931264; FJ931265; FJ931266; FJ931267; FJ931268; FJ931269; FJ931270; FJ931271; FJ931272; FJ931273; FJ931274; FJ931275; FJ931276; FJ931277; FJ931278; FJ931279; FJ931280; FJ931281; FJ931282; FJ931283; FJ931284; FJ931285; FJ931286; FJ931287; FJ931288; FJ931289; FJ931290; FJ931291; FJ931292; FJ931293; FJ931294; FJ931295; FJ931296; FJ931297; FJ931298; FJ931299; FJ931300; FJ931301; FJ931302; FJ931303; FJ931304; FJ931305; FJ931306; FJ931307; FJ931308; FJ931309; FJ931310; FJ931311; FJ931312; FJ931313; FJ931314; FJ931315; FJ931316; FJ931317; FJ931318; FJ931319; FJ931320; FJ931321; FJ931322; FJ931323; FJ931324; FJ931325; FJ931326; FJ931327; FJ931328; FJ931329; FJ931330; FJ931331; FJ931332; FJ931333; FJ931334; FJ931335; FJ931336; FJ931337; FJ931338; FJ931339; FJ931340; FJ931341; FJ931342; FJ931343; FJ931344; FJ931345; FJ931346; FJ931347; FJ931348; FJ931349; FJ931350; FJ931351; FJ931352; FJ931353; FJ931354; FJ931355; FJ931356; FJ931357; FJ931358; FJ931359; FJ931360; FJ931361; FJ931362; FJ931363; FJ931364; FJ931365; FJ931366; FJ931367; FJ931368; FJ931369; FJ931370; FJ931371; FJ931372; FJ931373; FJ931374; FJ931375; FJ931376; FJ931377; FJ931378; FJ931379; FJ931380; FJ931381; FJ931382; FJ931383; FJ931384; FJ931385; FJ931386; FJ931387; FJ931388; FJ931389; FJ931390; FJ931391; FJ931392; FJ931393; FJ931394; FJ931395; FJ931396; FJ931397; FJ931398; FJ931399; FJ931400; FJ931401; FJ931402; FJ931403; FJ931404; FJ931405; FJ931406; FJ931407; FJ931408; FJ931409; FJ931410; FJ931411; FJ931412; FJ931413; FJ931414; FJ931415; FJ931416; FJ931417; FJ931418; FJ931419; FJ931420; FJ931421; FJ931422; FJ931423; FJ931424; FJ931425; FJ931426; FJ931427; FJ931428; FJ931429; FJ931430; FJ931431; FJ931432; FJ931433; FJ931434; FJ931435; FJ931436; FJ931437; FJ931438; FJ931439; FJ931440; FJ931441; FJ931442; FJ931443; FJ931444; FJ931445; FJ931446; FJ931447; FJ931448; FJ931449; FJ931450; FJ931451; FJ931452; FJ931453; FJ931454; FJ931455; FJ931456; FJ931457; FJ931458; FJ931459; FJ931460 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Amino Acid Substitution / genetics Anti-HIV Agents / pharmacology, therapeutic use* Antiretroviral Therapy, Highly Active* Drug Resistance, Viral* Genotype HIV Infections / drug therapy*, virology* HIV Protease HIV Reverse Transcriptase / genetics HIV-1 / classification, drug effects*, genetics, isolation & purification Humans Molecular Sequence Data Mutation, Missense* Nigeria Sequence Analysis, DNA Treatment Failure Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
U01 AI025915-18/AI/NIAID NIH HHS; U51HA02522//PHS HHS; UO1 AI025915/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; EC 2.7.7.49/HIV Reverse Transcriptase; EC 3.4.23.-/HIV Protease; EC 3.4.23.-/p16 protease, Human immunodeficiency virus 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Susceptibility to Simian Immunodeficiency Virus Ex Vivo Predicts Outcome of a Prime-Boost Vaccine Af...
Next Document: Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Na??ve Subjects on Emtricit...